ACS Medicinal Chemistry Letters
Letter
protein arginine methyltransferase PRMT5 as a candidate therapeutic
target in glioblastoma. Cancer Res. 2014, 74, 1752−65.
(9) Gonsalvez, G. B.; Tian, L.; Ospina, J. K.; Boisvert, F. M.; Lamond,
A. I.; Matera, A. G. Two distinct arginine methyltransferases are
required for biogenesis of Sm-class ribonucleoproteins. J. Cell Biol.
2007, 178, 733−40.
(10) Yao, R.; Jiang, H.; Ma, Y.; Wang, L.; Du, J.; Hou, P.; Gao, Y.;
Zhao, L.; Wang, G.; Zhang, Y.; Liu, D. X.; Huang, B.; Lu, J. PRMT7
induces epithelial-to-mesenchymal transition and promotes metastasis
in breast cancer. Cancer Res. 2014, 74, 5656−67.
(11) Antonysamy, S.; Bonday, Z.; Campbell, R. M.; Doyle, B.;
Druzina, Z.; Gheyi, T.; Han, B.; Jungheim, L. N.; Qian, Y.; Rauch, C.;
Russell, M.; Sauder, J. M.; Wasserman, S. R.; Weichert, K.; Willard, F.
S.; Zhang, A.; Emtage, S. Crystal structure of the human
PRMT5:MEP50 complex. Proc. Natl. Acad. Sci. U.S.A. 2012, 109,
17960−5.
(12) Ho, M. C.; Wilczek, C.; Bonanno, J. B.; Xing, L.; Seznec, J.;
Matsui, T.; Carter, L. G.; Onikubo, T.; Kumar, P. R.; Chan, M. K.;
Brenowitz, M.; Cheng, R. H.; Reimer, U.; Almo, S. C.; Shechter, D.
Structure of the arginine methyltransferase PRMT5-MEP50 reveals a
mechanism for substrate specificity. PLoS One 2013, 8, e57008.
(13) Daigle, S. R.; Olhava, E. J.; Therkelsen, C. A.; Majer, C. R.;
Sneeringer, C. J.; Song, J.; Johnston, L. D.; Scott, M. P.; Smith, J. J.;
Xiao, Y.; Jin, L.; Kuntz, K. W.; Chesworth, R.; Moyer, M. P.; Bernt, K.
M.; Tseng, J. C.; Kung, A. L.; Armstrong, S. A.; Copeland, R. A.;
Richon, V. M.; Pollock, R. M. Selective killing of mixed lineage
leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer
Cell 2011, 20, 53−65.
(14) Yu, W.; Chory, E. J.; Wernimont, A. K.; Tempel, W.; Scopton,
A.; Federation, A.; Marineau, J. J.; Qi, J.; Barsyte-Lovejoy, D.; Yi, J.;
Marcellus, R.; Iacob, R. E.; Engen, J. R.; Griffin, C.; Aman, A.;
Wienholds, E.; Li, F.; Pineda, J.; Estiu, G.; Shatseva, T.; Hajian, T.; Al-
Awar, R.; Dick, J. E.; Vedadi, M.; Brown, P. J.; Arrowsmith, C. H.;
Bradner, J. E.; Schapira, M. Catalytic site remodelling of the DOT1L
methyltransferase by selective inhibitors. Nat. Commun. 2012, 3, 1288.
(15) van Haren, M.; van Ufford, L. Q.; Moret, E. E.; Martin, N. I.
Synthesis and evaluation of protein arginine N-methyltransferase
inhibitors designed to simultaneously occupy both substrate binding
sites. Org. Biomol. Chem. 2014, 13, 549−60.
(16) Dowden, J.; Hong, W.; Parry, R. V.; Pike, R. A.; Ward, S. G.
Toward the development of potent and selective bisubstrate inhibitors
of protein arginine methyltransferases. Bioorg. Med. Chem. Lett. 2010,
20, 2103−5.
(17) Schapira, M.; Ferreira de Freitas, R. Structural biology and
chemistry of protein arginine methyltransferases. MedChemComm
2014, 5, 1779−88.
(18) Troffer-Charlier, N.; Cura, V.; Hassenboehler, P.; Moras, D.;
Cavarelli, J. Functional insights from structures of coactivator-
associated arginine methyltransferase 1 domains. EMBO J. 2007, 26,
4391−401.
(19) Boisvert, F. M.; Cote, J.; Boulanger, M. C.; Richard, S. A
proteomic analysis of arginine-methylated protein complexes. Mol. Cell
Proteomics 2003, 2, 1319−30.
(20) Herrmann, F.; Pably, P.; Eckerich, C.; Bedford, M. T.;
Fackelmayer, F. O. Human protein arginine methyltransferases in
vivo–distinct properties of eight canonical members of the PRMT
family. J. Cell Sci. 2009, 122, 667−77.
(21) Yang, Y.; Bedford, M. T. Protein arginine methyltransferases
and cancer. Nat. Rev. Cancer 2013, 13, 37−50.
(22) Tee, W. W.; Pardo, M.; Theunissen, T. W.; Yu, L.; Choudhary,
J. S.; Hajkova, P.; Surani, M. A. Prmt5 is essential for early mouse
development and acts in the cytoplasm to maintain ES cell
pluripotency. Genes Dev. 2010, 24, 2772−7.
(23) Karkhanis, V.; Wang, L.; Tae, S.; Hu, Y. J.; Imbalzano, A. N.; Sif,
S. Protein arginine methyltransferase 7 regulates cellular response to
DNA damage by methylating promoter histones H2A and H4 of the
polymerase delta catalytic subunit gene, POLD1. J. Biol. Chem. 2012,
287, 29801−14.
AUTHOR INFORMATION
Corresponding Author
■
Author Contributions
∥These authors contributed equally to this work. The
manuscript was written through contributions of all authors.
All authors have given approval to the final version of the
manuscript.
Funding
The SGC is a registered charity (number 1097737) that
receives funds from AbbVie, Bayer, Boehringer Ingelheim,
Genome Canada through the Ontario Genomics Institute
[OGI-055], GlaxoSmithKline, Janssen, Lilly Canada, Merck, the
Novartis Research Foundation, the Ontario Ministry of
Economic Development and Innovation, Pfizer, Takeda, and
the Wellcome Trust [092809/Z/10/Z].
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
We would like to thank Elisa Gibson and Taraneh Hajian for
protein purification support.
■
ABBREVIATIONS
SAM, S-adenosylmethionine; SAH, S-adenosine homocysteine
■
REFERENCES
■
(1) Bedford, M. T.; Clarke, S. G. Protein arginine methylation in
mammals: who, what, and why. Mol. Cell 2009, 33, 1−13.
(2) Migliori, V.; Muller, J.; Phalke, S.; Low, D.; Bezzi, M.; Mok, W.
C.; Sahu, S. K.; Gunaratne, J.; Capasso, P.; Bassi, C.; Cecatiello, V.; De
Marco, A.; Blackstock, W.; Kuznetsov, V.; Amati, B.; Mapelli, M.;
Guccione, E. Symmetric dimethylation of H3R2 is a newly identified
histone mark that supports euchromatin maintenance. Nat. Struct. Mol.
Biol. 2012, 19, 136−44.
(3) Zurita-Lopez, C. I.; Sandberg, T.; Kelly, R.; Clarke, S. G. Human
protein arginine methyltransferase 7 (PRMT7) is a type III enzyme
forming omega-NG-monomethylated arginine residues. J. Biol. Chem.
2012, 287, 7859−70.
(4) Zhao, Q.; Rank, G.; Tan, Y. T.; Li, H.; Moritz, R. L.; Simpson, R.
J.; Cerruti, L.; Curtis, D. J.; Patel, D. J.; Allis, C. D.; Cunningham, J.
M.; Jane, S. M. PRMT5-mediated methylation of histone H4R3
recruits DNMT3A, coupling histone and DNA methylation in gene
silencing. Nat. Struct. Mol. Biol. 2009, 16, 304−11.
(5) Andreu-Perez, P.; Esteve-Puig, R.; de Torre-Minguela, C.; Lopez-
Fauqued, M.; Bech-Serra, J. J.; Tenbaum, S.; Garcia-Trevijano, E. R.;
Canals, F.; Merlino, G.; Avila, M. A.; Recio, J. A. Protein arginine
methyltransferase 5 regulates ERK1/2 signal transduction amplitude
and cell fate through CRAF. Sci. Signaling 2011, 4, ra58.
(6) Bezzi, M.; Teo, S. X.; Muller, J.; Mok, W. C.; Sahu, S. K.; Vardy,
L. A.; Bonday, Z. Q.; Guccione, E. Regulation of constitutive and
alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in
sensing defects in the spliceosomal machinery. Genes Dev. 2013, 27,
1903−16.
(7) Meister, G.; Eggert, C.; Buhler, D.; Brahms, H.; Kambach, C.;
Fischer, U. Methylation of Sm proteins by a complex containing
PRMT5 and the putative U snRNP assembly factor pICln. Curr. Biol.
2001, 11, 1990−4.
(8) Yan, F.; Alinari, L.; Lustberg, M. E.; Martin, L. K.; Cordero-
Nieves, H. M.; Banasavadi-Siddegowda, Y.; Virk, S.; Barnholtz-Sloan,
J.; Bell, E. H.; Wojton, J.; Jacob, N. K.; Chakravarti, A.; Nowicki, M.
O.; Wu, X.; Lapalombella, R.; Datta, J.; Yu, B.; Gordon, K.; Haseley,
A.; Patton, J. T.; Smith, P. L.; Ryu, J.; Zhang, X.; Mo, X.; Marcucci, G.;
Nuovo, G.; Kwon, C. H.; Byrd, J. C.; Chiocca, E. A.; Li, C.; Sif, S.;
Jacob, S.; Lawler, S.; Kaur, B.; Baiocchi, R. A. Genetic validation of the
411
ACS Med. Chem. Lett. 2015, 6, 408−412